Literature DB >> 32344016

Update on the cellular and molecular aspects of lupus nephritis.

Eleni Frangou1, Spyros Georgakis2, George Bertsias3.   

Abstract

Recent progress has highlighted the involvement of a variety of innate and adaptive immune cells in lupus nephritis. These include activated neutrophils producing extracellular chromatin traps that induce type I interferon production and endothelial injury, metabolically-rewired IL-17-producing T-cells causing tissue inflammation, follicular and extra-follicular helper T-cells promoting the maturation of autoantibody-producing B-cells that may also sustain the formation of germinal centers, and alternatively activated monocytes/macrophages participating in tissue repair and remodeling. The role of resident cells such as podocytes and tubular epithelial cells is increasingly recognized in regulating the local immune responses and determining the kidney function and integrity. These findings are corroborated by advanced, high-throughput genomic studies, which have revealed an unprecedented amount of data highlighting the molecular heterogeneity of immune and non-immune cells implicated in lupus kidney disease. Importantly, this research has led to the discovery of putative pathogenic pathways, enabling the rationale design of novel treatments.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoantibodies; Cytokines; Macrophages; Podocytes; RNA sequencing; Renal tubular epithelial cells

Mesh:

Substances:

Year:  2020        PMID: 32344016     DOI: 10.1016/j.clim.2020.108445

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  14 in total

Review 1.  IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases.

Authors:  Hao Li; George C Tsokos
Journal:  Clin Rev Allergy Immunol       Date:  2020-11-13       Impact factor: 8.667

Review 2.  Lupus Nephritis: Improving Treatment Options.

Authors:  Myrto Kostopoulou; Sofia Pitsigavdaki; George Bertsias
Journal:  Drugs       Date:  2022-04-29       Impact factor: 9.546

Review 3.  Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases.

Authors:  Nathalie Burg; Jane E Salmon; Timothy Hla
Journal:  Nat Rev Rheumatol       Date:  2022-05-04       Impact factor: 20.543

Review 4.  Endothelial function and endothelial progenitor cells in systemic lupus erythematosus.

Authors:  Anselm Mak; Jerry Kok Yen Chan
Journal:  Nat Rev Rheumatol       Date:  2022-04-07       Impact factor: 20.543

5.  Umbilical Cord Mesenchymal Stem Cells Ameliorate Kidney Injury in MRL/Ipr Mice Through the TGF-β1 Pathway.

Authors:  Chunkai Huang; Mingyao Meng; Shuo Li; Shiyuan Liu; Lin Li; Yanjun Su; Hui Gao; Shan He; Yiyi Zhao; Min Zhang; Zongliu Hou; Wenju Wang; Xiaodan Wang
Journal:  Front Cell Dev Biol       Date:  2022-04-05

Review 6.  Targeting DAMPs with nucleic acid scavengers to treat lupus.

Authors:  Lyra B Olson; Nicole I Hunter; Rachel E Rempel; Bruce A Sullenger
Journal:  Transl Res       Date:  2022-03-02       Impact factor: 10.171

Review 7.  Apolipoprotein L1 and mechanisms of kidney disease susceptibility.

Authors:  Leslie A Bruggeman; John R Sedor; John F O'Toole
Journal:  Curr Opin Nephrol Hypertens       Date:  2021-05-01       Impact factor: 2.894

Review 8.  B Cell Aberrance in Lupus: the Ringleader and the Solution.

Authors:  YuXue Nie; Lidan Zhao; Xuan Zhang
Journal:  Clin Rev Allergy Immunol       Date:  2021-02-03       Impact factor: 8.667

9.  Interleukin-12 exacerbates symptoms in an MRL/MpJ-Faslpr mouse model of systemic lupus erythematosus.

Authors:  Ling Li; Xiaojun Sun; Sisi Wu; Xin Yuan; Bingxin Liu; Xueping Zhou
Journal:  Exp Ther Med       Date:  2021-04-15       Impact factor: 2.447

10.  Alport syndrome combined with lupus nephritis in a Chinese family: A case report.

Authors:  Hui-Fang Liu; Qing Li; You-Qun Peng
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.